DOCSLIB.ORG

For Peer Review Only

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For Peer Review Only BMJ Open BMJ Open: first published as 10.1136/bmjopen-2013-003424 on 24 September 2013. Downloaded from BMJ Open: first published as 10.1136/bmjopen-2013-003424 on 24 September 2013. Downloaded from Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000-2010 ForJournal: peerBMJ Open review only Manuscript ID: bmjopen-2013-003424 Article Type: Research Date Submitted by the Author: 17-Jun-2013 Complete List of Authors: Ehrenstein, Vera; Aarhus University Hospital, Department of Clinical Epidemiology Hernandez, Rohini; Amgen, Inc., Center for Observational Research Ulrichsen, Sinna; Aarhus University Hospital, Department of Clinical Epidemiology Rungby, Jørgen; Aarhus University Hospital, Department of Biomedicine - Pharmacology Lash, Timothy; Emory University Rollins School of Public Health, Department of Epidemiology Riis, Anders; Aarhus University Hospital, Department of Clinical Epidemiology Li, Lin; Boston University School of Medicine, Boston Collaborative Drug Surveillance Program Toft Sørensen, Henrik; Aarhus University Hospital, Department of Clinical Epidemiology http://bmjopen.bmj.com/ Jick, Sn; Boston University, ; Boston University School of Medicine, Boston http://bmjopen.bmj.com/ Collaborative Drug Surveillance Program <b>Primary Subject Epidemiology Heading</b>: Secondary Subject Heading: Pharmacology and therapeutics, Public health diabetes mellitus, drug safety, glucose-lowering drugs, rosiglitazone, Keywords: on September 27, 2021 by guest. Protected copyright. thiazolidinediones on September 27, 2021 by guest. Protected copyright. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 50 BMJ Open BMJ Open: first published as 10.1136/bmjopen-2013-003424 on 24 September 2013. Downloaded from 1 2 Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 3 4 2000-2010 5 6 7 8 9 10 1* 2,3** 1 4 1,5 1 11 V. Ehrenstein, R. K. Hernandez, S. P. Ulrichsen, J. Rungby, T. L. Lash, A.H. Riis, L. 12 13 Li,2 H. T. Sørensen,1 S. S. Jick2 14 15 For peer review only 16 17 1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark 18 19 2 20 Boston Collaborative Drug Surveillance Program (BCDSP), Boston University School of 21 22 Public Health, Lexington, MA, USA 23 24 3Amgen, Inc., Thousand Oaks, CA, USA 25 26 4Department of Biomedicine - Pharmacology, Aarhus University, Aarhus, Denmark 27 28 5 29 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, 30 31 GA, USA 32 33 34 http://bmjopen.bmj.com/ 35 *Correspondence to: V. Ehrenstein [email protected] 36 37 **Dr. Hernandez was affiliated with BCDSP at the time the work for this project was 38 39 conducted. 40 41 42 43 on September 27, 2021 by guest. Protected copyright. 44 45 46 Words: abstract 241, main text 2,553 47 48 49 1 Figure, 5 Tables 50 51 52 53 54 55 56 57 Page 1 of 22 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open Page 2 of 50 BMJ Open: first published as 10.1136/bmjopen-2013-003424 on 24 September 2013. Downloaded from 1 2 Article summary 3 4 5 Article focus (up to three bullet points on the research questions or hypotheses addressed); 6 • Rosiglitazone is a second-line oral hypoglycaemic agent, which was sold in the 7 European Union starting in 2000; in a series of regulatory decision, its use was 8 restricted and ultimately suspended in Europe in September 2010 9 • This article examines utilization of rosiglitazone in Denmark and the United 10 Kingdom, in 2000-2010 11 • On the patient level, this article explores changes in glycaemic control following 12 discontinuation of rosiglitazone 13 14 15 Key messagesFor (up to three peer bullet points showingreview the key messages only or significance of the 16 study) 17 • Following a 2007 publication of a meta-analysis showing increased cardiovascular 18 morbidity associated with rosiglitazone, use of the drug declined sharply and 19 irreversibly in Denmark and in the UK; this predated the official suspension of the 20 drug by the European Medicines Agency in 2010 21 • On the patient level, observed mean changes in fasting plasma glucose and glycated 22 haemoglobin A1c were slight in patients who discontinued rosiglitazone 23 24 25 Strengths and limitations of this study 26 • The study makes use of population based routine medical databases in two European 27 countries, which are likely to reflect typical clinical practice 28 • Despite differences in record generation mechanisms in the two databases, results 29 were overall concordant 30 31 • Automated prescription and dispensation data may have imprecisely measured 32 initiation and discontinuation of medication intake 33 34 http://bmjopen.bmj.com/ 35 36 37 38 39 40 41 42 43 on September 27, 2021 by guest. Protected copyright. 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 3 of 50 BMJ Open BMJ Open: first published as 10.1136/bmjopen-2013-003424 on 24 September 2013. Downloaded from 1 2 Abstract 3 4 5 Objectives To evaluate the impact of risk minimisation policies on use of rosiglitazone- 6 7 containing products and on glycaemic control among patients in Denmark and the United 8 9 Kingdom (UK). 10 11 Design, setting and participants We used population-based data from the Aarhus University 12 13 Prescription Database (AUPD) in northern Denmark and the General Practice Research 14 15 Database (GPRD)For in the peer UK. review only 16 17 Main outcome measures We examined use of rosiglitazone during its entire period of 18 19 availability on the European market (2000–2010) and evaluated changes in glycated 20 21 haemoglobin-A (HbA ) and fasting plasma glucose (FPG) levels among patients 22 1c 1c 23 discontinuing this drug. 24 25 26 Results During 2000–2010, 2,321 patients with records in the AUPD used rosiglitazone in 27 28 northern Denmark and 25,428 patients with records in the GPRD used it in the UK. The 29 30 proportion of rosiglitazone users among all users of oral hypoglycaemic agents (OHA) peaked 31 32 at 4% in the AUPD and 15% in the GPRD in May 2007. Twelve months after discontinuation 33 of rosiglitazone-containing products, the mean change in HbA1c was –0.16% (95% confidence 34 http://bmjopen.bmj.com/ 35 36 interval [CI]: –3.4%, 3.1%) in northern Denmark and –0.17% (95% CI: –0.21%, 0.13%) in the 37 38 UK. Corresponding mean changes in FPG were 0.01 mmol/L (95% CI: –7.3 mmol/L, 7.3 39 40 mmol/L) and 0.03 mmol/L (95% CI: –0.22 mmol/L, 0.28 mmol/L). 41 42 Conclusions Publication of evidence concerning potential cardiovascular risks of rosiglitazone on September 27, 2021 by guest. Protected copyright. 43 44 was associated with a irreversible decline in use of rosiglitazone-containing products in 45 46 Denmark and the UK. Mean changes in HbA1c and FPG after drug discontinuation were slight. 47 48 49 Key words: diabetes mellitus, drug safety, glucose-lowering drugs, rosiglitazone, 50 51 thiazolidinediones 52 53 54 55 56 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open Page 4 of 50 BMJ Open: first published as 10.1136/bmjopen-2013-003424 on 24 September 2013. Downloaded from 1 2 Introduction 3 4 5 Since first marketed in the European Union in 2000, rosiglitazone has been subject to 6 1-9 7 several risk-benefit assessments, especially concerning cardiovascular safety . In a May 8 9 2007 meta-analysis published in the New England Journal of Medicine, Nissen and Wolski 10 2 11 reported increased cardiovascular morbidity associated with rosiglitazone use . In 2008, the 12 13 European Medicines Agency (EMA) amended the rosiglitazone product label, adding coronary 14 15 syndrome toFor the list of contraindicationspeer andreview inserting a warning aboutonly potentially increased 16 10 17 risk of ischemic events . At the time of this label amendment, EMA concluded “that the 18 19 benefits of [...] rosiglitazone [...] in the treatment of type 2 diabetes continue to outweigh their 20 21 risks” 11. In June 2010, Nissen and Wolski updated their meta-analysis, confirming the finding 22 23 of an increased risk of myocardial infarction (but not the original finding of increased all- 24 25 cause mortality) in association with rosiglitazone use 12. In July 2010, Graham and colleagues 26 27 published a paper in JAMA, based on data from US Medicare beneficiaries, showing increased 28 29 risks of several cardiovascular events, as well as all-cause mortality, in a comparison of 30 31 rosiglitazone users with pioglitazone users 7. Following these two publications, on 22 32 33 September 2010, the EMA recommended suspension of use of all rosiglitazone-containing 34 http://bmjopen.bmj.com/ 35 products in the European Union 13. The European Commission subsequently mandated 36 37 suspension of the drug, citing absence of unique therapeutic benefits outweighing its risks 14. 38 39 Here we report results of an EMA-commissioned study on the impact of labelling 40 41 changes and findings reported in scientific publications on utilisation of rosiglitazone- 42 43 on September 27, 2021 by guest. Protected copyright. 44 containing products in Europe. On the population level, we examined changes in use of 45 46 rosiglitazone-containing products over the entire period when rosiglitazone was available on 47 48 the market. On the patient level, we assessed the impact of rosiglitazone discontinuation on 49 50 glycaemic control and reported oral hypoglycaemic agents prescribed after post-suspension 51 52 discontinuation of rosiglitazone. 53 54 55 56 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 5 of 50 BMJ Open BMJ Open: first published as 10.1136/bmjopen-2013-003424 on 24 September 2013.
Load more

Recommended publications
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Penetrating Topical Pharmaceutical Compositions Containing N-\2-Hydroxyethyl\Pyrrolidone
    Europaisches Patentamt ® J European Patent Office © Publication number: 0 129 285 Office europeen des brevets A2 (12) EUROPEAN PATENT APPLICATION © Application number: 84200823.7 ©Int CI.3: A 61 K 47/00 A 61 K 31/57, A 61 K 45/06 © Date of filing: 12.06.84 © Priority: 21.06.83 US 506273 © Applicant: THE PROCTER & GAMBLE COMPANY 301 East Sixth Street Cincinnati Ohio 45201 (US) © Date of publication of application: 27.12.84 Bulletin 84/52 © Inventor: Cooper, Eugene Rex 2425 Ambassador Drive © Designated Contracting States: Cincinnati Ohio 4523KUS) BE CH DE FR GB IT LI NL SE © Representative: Suslic, Lydia et al, Procter & Gamble European Technical Center Temseiaan 100 B-1820 Strombeek-Bever(BE) © Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl)pyrrolidone. Topical pharmaceutical compositions comprising a pharmaceutically-active agent and a novel, penetration- enhancing vehicle or carrier are disclosed. The vehicle or carrier comprises a binary combination of N-(2-Hydroxyethyl) pyrrolidone and a "cell-envelope disordering compound". The compositions provide marked transepidermal and per- cutaneous delivery of the active selected. A method of treat- ing certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed. TECHNICAL FIELD i The present invention relates to compositions which enhance the utility of certain pharmaceutically-active agents by effectively delivering these agents through the integument. Because of the ease of access, dynamics of application, large surface area, vast exposure to the circulatory and lymphatic networks, and non-invasive nature of the treatment, the delivery of pharmaceutically-active agents through the skin has long been a promising concept.
    [Show full text]
  • Ш„ ^Гг Тііи CLINICAL PHARMACOLOGICAL STUDIES on TIENILIC ACID and FUROSEMIDE Promotores: Prof
    D D π Ш π α π • Q ÛDD fDSDUO Q ^г^ ш„ ^гг тііи CLINICAL PHARMACOLOGICAL STUDIES ON TIENILIC ACID AND FUROSEMIDE Promotores: Prof. dr F. W. J. GRIBNAU Prof. dr С. Α. Μ. van GINNEKEN CLINICAL PHARMACOLOGICAL STUDIES ON TIENILIC ACID AND FUROSEMIDE PROEFSCHRIFT ter verkrijging van de graad van doctor in de Geneeskunde aan de Katholieke Universiteit te Nijmegen, op gezag van de rector magnificus Prof. dr J. H. G. I. Giesbers, volgens het besluit van het college van dekanen in het openbaar te verdedigen op donderdag 24 maart 1983 des namiddags te 2 uur precies door ADRIANUS LAMBERTUS MARIA KERREMANS geboren te Roosendaal И krips repro meppel The studies presented in this thesis were performed in - the Department of Internal Medicine - the Institute of Pharmacology of the University of Nijmegen, The Netherlands; and in - the Nursing home 'Irene" H. Landstichting - the Canisius-Wilhelmina Hospital Nijmegen Aan Mariette Jos, Sanne en Mechteld Aan mijn ouders CONTENTS Chapter I GENERAL INTRODUCTION AND PROBLEM STATEMENT page Chapter II DIURETICS 2.1 renal transport of sodium and chloride 2.2 renal transport of uric acid 2.3 site of action and mode of action of diuretics 2.4 tienilic acid 2.5 furosemide references Chapter III SOME FACTORS INFLUENCING DRUG RESPONSE 2 3.1 influence of age on pharmacokinetics and pharmacodynamics 3.2 influence of long-term treatment 3.3 congestive heart failure and its influence on sodium homoeostasis and on disposition and effect of diuretics 3.4 diuretic resistance in congestive heart failure references Chapter IV METHODS 4 4.1 HPLC 4.2 protein binding of drugs 4.3 pharmacokinetics 4.4 dose-response curves references Chapter V PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF TIE- 6 NILIC ACID IN HEALTHY VOLUNTEERS Eur J Clin Pharmacol 1982, 22, 515-521.
    [Show full text]
  • Azosemide Is More Potent Than Bumetanide and Various Other Loop
    www.nature.com/scientificreports OPEN Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium- Received: 21 November 2017 Accepted: 14 June 2018 potassium-chloride-cotransporter Published: xx xx xxxx human variants hNKCC1A and hNKCC1B Philip Hampel 1,2, Kerstin Römermann1, Nanna MacAulay 3 & Wolfgang Löscher1,2 The Na+–K+–2Cl− cotransporter NKCC1 plays a role in neuronal Cl− homeostasis secretion and represents a target for brain pathologies with altered NKCC1 function. Two main variants of NKCC1 have been identifed: a full-length NKCC1 transcript (NKCC1A) and a shorter splice variant (NKCC1B) that is particularly enriched in the brain. The loop diuretic bumetanide is often used to inhibit NKCC1 in brain disorders, but only poorly crosses the blood-brain barrier. We determined the sensitivity of the two human NKCC1 splice variants to bumetanide and various other chemically diverse loop diuretics, using the Xenopus oocyte heterologous expression system. Azosemide was the most potent NKCC1 inhibitor (IC50s 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B), being about 4-times more potent than bumetanide. Structurally, a carboxylic group as in bumetanide was not a prerequisite for potent NKCC1 inhibition, whereas loop diuretics without a sulfonamide group were less potent. None of the drugs tested were selective for hNKCC1B vs. hNKCC1A, indicating that loop diuretics are not a useful starting point to design NKCC1B-specifc compounds. Azosemide was found to exert an unexpectedly potent inhibitory efect and as a non-acidic compound, it is more likely to cross the blood-brain barrier than bumetanide. Te Na+–K+–2Cl− cotransporter NKCC1 (encoded by SLC12A2) plays an important role in Cl- uptake in neu- rons both in developing brain and in adult sensory neurons1,2.
    [Show full text]
  • A New Diuretic That Does Not Reduce Renal Handling of Uric Acid in Rats, S-8666 Yukio YONETANI, Kazumi IWAKI, Mitsuo ISHII and H
    A New Diuretic That Does Not Reduce Renal Handling of Uric Acid in Rats, S-8666 Yukio YONETANI, Kazumi IWAKI, Mitsuo ISHII and Hiroshi HARADA ShionogiResearch Laboratories, Shionogi & Co., Ltd., Fukushima-ku,Osaka 553, Japan AcceptedJanuary 6, 1987 Abstract-The uric acid-retaining effects of diuretics were studied using sodium restricted spontaneously hypertensive rats. Test agents were administered orally once a day for two weeks. Diuretic thiazides such as trichlormethiazide and hydrochlorothiazide and loop diuretics such as furosemide and indacrinone clearly reduced the renal function for uric acid excretion in treatment which produced major effects such as diuresis, saluresis and hypotension. However, a new diuretic with uricosuric activity, S-8666, developed in our laboratories, had no effect on the renal handling of uric acid at doses which showed major effects similar to those of other diuretics. The results should aid the understanding of the utility of S-8666 as a new diuretic antihypertensive which does not cause hyperuricemia during therapy. The high incidence of hyperuricemia to 8666), which is active in rats and chimpanzees hypertension (1, 2) has required the develop (8). We tried to find whether S-8666 affects ment of a new generation of diuretic anti uric acid excretion at a dose which produces hypertensives, which do not cause hyper a major effect, in comparison with other uricemia. Uricosuric diuretics such as tienilic diuretics. Our findings support the utility of acid (3) and indacrinone (4) have recently S-8666 as a new diuretic antihypertensive been studied as such candidates. However, which does not cause hyperuricemia. the results have shown the need for careful testing (5, 6).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • Rapid Ultra High Performance Liquid Chromatography–Tandem Mass Spectrometry Method for Quantification of Ethacrynic Acidin Human Plasma
    IOSR Journal of Biotechnology and Biochemistry (IOSR-JBB) ISSN: 2455-264X, Volume 4, Issue 1 (Jan. - Feb 2018), PP 01-11 www.iosrjournals.org Rapid Ultra High Performance Liquid Chromatography–Tandem Mass Spectrometry Method for Quantification of Ethacrynic Acidin Human Plasma Smith Christian1,*2, Rashmikant Patel2, Shivprakash1 1Synchron Research Services Private Limited, Synchron House, 3rd Floor, Near Gurudwara, S-G Highway, Ahmedabad, Gujarat State, India 2Department of Chemistry, Municipal Arts & Urban Bank Science College, Mehsana, Gujarat State, India Corresponding Author:Smith Christian Abstract:A sensitive and high throughput high performance liquid chromatography tandem mass spectrometry (HPLC–MS/MS) method has been developed for the determination of ethacrynic in human plasma. Sample preparation involved liquid–liquid extraction for ethacrynic and ethacrynic D5 as the internal standard (IS) in ethyl acetate from 200 μL human plasma. The chromatographic separation is achieved on a shimadzu HPLC and Gemini-NX 5μ C18 110 A° (50 X 4.6, mm) analytical column using an isocratic mobile phase, consisting of 0.1 % formic acid in water–acetonitrile (30:70, v/v). Detection was carried out on a tandem mass spectrometer inmultiple reaction monitoring mode using a negative electro pressure ionization interface.The method has been validated in linear range of 4.997-1000.283 ng/mL. The method is rugged and rapid with a total run time of 3.0 min and is applied to a bioequivalence study of 25 mg tablet formulation in 48 healthy Indian male subjects under fasting condition. Keywords: Ethacrynic Acid, HPLC–MS/MS, Electrospray ionization, Bioequivalence, Human plasma ------------------------------------------------------------------------------------------------------------------------------------ Date of Submission: 16-01-2018 Date of acceptance: 31-01-2018 ----------------------------------------------------------------------------------------------------------------------------- ------ I.
    [Show full text]
  • Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
    WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD).
    [Show full text]
  • Chem. Pharm. Bull. 52(7) 836-841 (2004)
    836 Chem. Pharm. Bull. 52(7) 836—841 (2004) Vol. 52, No. 7 Characterization of the CYP2C8 Active Site by Homology Modeling Toshimasa TANAKA,* Naomi KAMIGUCHI, Teruaki OKUDA, and Yoshio YAMAMOTO Pharmaceutical Research Division, Takeda Chemical Industries, Ltd.; 2–17–85 Juso-Honmachi, Yodogawa-ku, Osaka 532–8686, Japan. Received March 8, 2004; accepted April 14, 2004; published online April 19, 2004 To compare the features of the active sites of CYP2C8, CYP2C9, and CYP2C19, homology modeling was performed based on the crystallographic coordinates of mammalian CYP2C5. It was found that CYP2C8 has a much larger pocket than the other forms due to the existence of an additional pocket. The approach to the addi- tional pocket is comprised of Ile102, Ser114, Leu208, Val366, and Ile476, and the side chains of Ser114, Val366, and Ile476, which are smaller than the corresponding residues in the other CYPs, enable access to the pocket. The general features of the active site in the CYP2C8 model are similar to those of the previously constructed CYP3A4 model, which may account for the 2 CYPs sharing some of their substrates. The CYP2C8 model was validated by examining the bound orientation of paclitaxel and showing that it is consistent with the formation of the 6-beta hydroxylated derivative during metabolism. Docked paclitaxel was found to form a hydrogen bond with the side chain of Asn 99, which is a characteristic residue of CYP2C8 and is located in the additional pocket. Descriptors for CYP2C8 and CYP2C9 substrates were also examined with the molecular operating envi- ronment (MOE). The descriptor by which CYP2C8 and CYP2C9 substrates were classified most distinctly was found to be molar refractivity, which might be related to the longer shape and more polar nature of the active site of CYP2C8 in the CYP2C subfamily.
    [Show full text]